unless anticoagulation is contraindicated. [20] Experience of using fondaparinux in the cancer population is limited. Prolonged prophylaxis for up to 30 days should be considered in cancer ...

For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban ...

On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

Given the aggressive natural history of VTE in cancer patients ... it is important to evaluate the efficacy and safety of anticoagulation specifically in the oncology population.